Figure 4. Kaplan-Meier Estimates of Probability of Relapse-Free Survival of the iCAβ International Network Cohort Registry²⁵ of 113 Patients With First-Ever Diagnosis of CAA-ri.².

Data are expressed as incidence probability (percentage). Definite and probable cerebral amyloid angiopathy–related inflammation (CAA-ri) (diagnostic category) diagnosed by clinical presentation, radiologic criteria, or pathologic findings.² Follow-up time defined as the time elapsed from the date of CAA-ri diagnosis to the date of each in-person visit or last follow-up available. Relapse-free survival defined as the time elapsed from the date of ascertained clinical and radiologic recovery to the date of first relapse, death, or last follow-up, whichever occurred first. Relapse-free survival estimated starting from a 3-month landmark (LM) by the Simon-Makuch method to include the delayed entry of patients with clinical recovery over the entire follow-up. Analysis included all the 90 recovered patients (n = 76 with definite/probable CAA-ri; n = 14 with possible CAA-ri with first-ever diagnosis received at baseline). Relapses occurred only in definite/probable CAA-ri (continuous blue line). Dashed blue lines indicate upper and lower 95% confidence interval (CI) of relapses in definite/probable CAA-ri. iCAβ = Inflammatory Cerebral Amyloid Angiopathy and Alzheimer's Disease βiomarkers;